Glaxo Manufacturing Initiative Will Yield $600 Mil. Annual Savings
Executive Summary
Glaxo Wellcome estimates that its manufacturing streamlining initiative "will be earnings enhancing in 2000" and will generate an annual benefit of over $600 mil. (L370 mil.) per annum in 2003.
You may also be interested in...
Glaxo/SB Merger Talks Resume After Management, Manufacturing Changes
Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.
Glaxo/SB Merger Talks Resume After Management, Manufacturing Changes
Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.
Wyeth-Ayerst To Produce Enbrel At Former Glaxo Wellferon Site
Wyeth-Ayerst plans to manufacture the rheumatoid arthritis therapy Enbrel at a West Greenwich, R.I. biopharmaceutical facility purchased from Glaxo.